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Abstract
Background: Although the World Health Organization (WHO) provides information on the number of TB patients
categorised as ‘‘other’’, there is limited information on treatment regimens or treatment outcomes for ‘‘other’’. Such
information is important, as inappropriate treatment can lead to patients remaining infectious and becoming a potential
source of drug resistance. Therefore, using a cohort of TB patients from a large registration centre in Lilongwe, Malawi, our
study determined the proportion of all TB re-treatment patients who were registered as ‘‘other’’, and described their
characteristics and treatment outcomes.
Methods: This retrospective observational study used routine program data to determine the proportion of all TB re-
treatment patients who were registered as ‘‘other’’ and describe their characteristics and treatment outcomes between
January 2006 and December 2008.
Results: 1,384 (12%) of 11,663 TB cases were registered as re-treatment cases. Of these, 898 (65%) were categorised as
‘‘other’’: 707 (79%) had sputum smear-negative pulmonary TB and 191 (21%) had extra pulmonary TB. Compared to the
smear-positive relapse, re-treatment after default (RAD) and failure cases, smear-negative ‘‘other’’ cases were older than 34
years and less likely to have their HIV status ascertained. Among those with known HIV status, ‘‘other’’ TB cases were more
likely to be HIV positive. Of TB patients categorised as ‘‘other’’, 462 (51%) were managed on the first-line regimen with a
treatment success rate of 63%.
Conclusion: A large proportion of re-treatment patients were categorised as ‘‘other’’. Many of these patients were HIV-
infected and over half were treated with a first-line regimen, contrary to national guidelines. Treatment success was low.
More attention to recording, diagnosis and management of these patients is warranted as incorrect treatment regimen and
poor outcomes could lead to the development of drug resistant forms of TB.
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Introduction
With an annual incidence of 260 tuberculosis (TB) cases per
100,000 population [1], TB continues to threaten the lives of many
people in Malawi. In the last 10 years, the number of previously-
treated TB cases increased from 5% to 11% (Malawi National TB
Programme,, unpublished data). This is of concern as these
patients may acquire drug resistance and, therefore, have poor
treatment outcomes [2][3]. The Malawi National TB Programme
(NTP) diagnoses, registers and treats all forms of TB following
international guidelines [4][5]. Previously-treated TB patients are
classified into four categories: relapse, failure, re-treatment after
default (RAD) and ‘‘other’’. According to Malawi National TB
guidelines, ‘‘other’’ includes chronic re-treatment TB patients,
patients with recurrent smear-negative pulmonary TB and extra-
pulmonary TB [4].
The categorization of TB patients as ‘‘other’’ may indicate poor
patient management. According to the World Health Organiza-
tion’s (WHO) Global Tuberculosis Control report on relapse,
failure, RAD and ‘‘other’’ for Africa, South-East Asia and Western
Pacific regions in 2007, about 35% of 581,000 TB re-treatment
cases were registered as ‘‘other’’ [1]. Although the WHO report
provides information on the number of patients categorised as
‘‘other’’, there are limited data on treatment regimens or
treatment outcomes for this group. A study conducted in India
found that TB patients categorized as ‘‘other’’ were treated with a
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to relapse, failure and RAD [6]. In a routine programme setting,
information on treatment regimen and outcomes is important as
inappropriate management of TB patients can lead to patients
remaining infectious and becoming a potential source of drug
resistance [7].
We therefore carried out a study at the largest TB registration
centre in Malawi to determine the numbers and proportions of
adult TB re-treatment patients categorised as ‘‘other’’. We also
documented what treatment regimens were used and patient
treatment outcomes for ‘‘other’’ TB patients, comparing them to
outcomes reported for previously-treated patients registered as
relapse, failure and RAD.
Methods
Setting
The study was conducted at Martin Preuss Centre (MPC) clinic
in Lilongwe, the largest TB registration centre in Malawi. MPC
registers 4,000 TB patients annually. Diagnosis of PTB is based on
clinical examination, sputum smear microscopy, and chest
radiography. In most cases, diagnosis of EPTB is made based on
radiography but it was also diagnosed bacteriogically or
histopathologically. For quality control, peripheral laboratories
send standard smears with known results to the central laboratory
at MPC every month; these smears are rechecked by central
laboratory technicians. Once diagnosed with TB, patients are
registered by the district TB officer and initiated on standardized
treatment regimens [4]. According to national guidelines, all re-
treatment patients should be treated with the standard WHO
category II regimen, consisting of two months of daily streptomy-
cin (S), rifampicin (R), Isoniazid (H), pyrazinamide (Z) and
ethambutol (E), followed by one month of RHZE and then five
months of RHE (2SRHZE/1RHZE/5RHE).
Approximately 30% of patients initiated and completed their
treatment at MPC; 70% initiated at MPC but chose to complete
their treatment at one of 18 peripheral health facilities. Treatment
cards for those who completed treatment at MPC remained with
the TB officer on site; treatment cards of patients who sought care
at peripheral health facilities were sent to, and maintained, at their
respective facilities during treatment. After completion of treat-
ment, the cards from peripheral sites should be returned to the
initial registration centre (MPC). Every six months, the district TB
officer visited peripheral health facilities to collect treatment cards
that were not returned. Treatment outcomes (‘‘cured’’, ‘‘treatment
completed’’, ‘‘died’’, ‘‘treatment failure’’, ‘‘defaulted’’ or ‘‘trans-
ferred-out’’) were updated in the TB Register at MPC from
treatment cards.
Study design and participants
This retrospective cohort study of re-treatment adult TB
patients (age$15 years) was conducted using routine program
data from TB registers and patient treatment cards collected from
January 2006 to December 2008 at MPC. The Malawi National
TB control program classifies previously treated patients as
follows: 1) ‘‘relapse’’=completed treatment but subsequently
developed active smear-positive pulmonary TB; 2) ‘‘failure’’=r-
emained sputum smear-positive at five months or more during
first-line treatment; 3) ‘‘re-treatment after default (RAD)’’=inter-
rupted treatment for more than two months and returned with
smear-positive TB; and 4) ‘‘other’’=not fulfilling any of the above
categories, including chronic cases [4].
Data collection and Data Analysis
Data extracted from registers for each patient included TB
registration number, registration date, age, gender, TB classifica-
tion, patient category, treatment regimen, initial sputum micros-
copy results and HIV status. The Malawi TB programme does not
routinely conduct culture tests and, as such, there were no culture
results captured in the national TB register. HIV status was only
documented from January 2007. Treatment outcomes were
extracted from treatment cards. Missing case registration data in
the TB registers were retrieved from treatment cards, if available.
Data were double-entered and cleaned in a custom-designed
MS Access database and analyzed in STATA 10. Since there was
a strong correlation between TB classification and patient
retreatment category, only patient category was considered for
further analysis. We categorized re-treatment patients in four
ways: smear-positive relapse, smear-positive RAD, smear-positive
failure and smear-negative ‘‘other’’. The ‘‘other’’ re-treatment
category consisted of smear-negative PTB and EPTB patients
except for 3 cases that were registered in 2006. These cases might
have been misclassified and were therefore excluded from further
analyses. The chi-square test for significance was used to compare
patient characteristics and patient re-treatment categories. Because
TB treatment outcomes are generally classified as either treatment
success or not, we modelled treatment outcome as a binary
variable of success versus all other treatment outcomes. Logistic
regression was then used to identify patient characteristics that
were independently associated with treatment success. The final
multivariable model was determined using forward selection,
including explanatory variables with a two-sided p-value of #0.05.
Age was included a priori in all multivariable models. The log-
likelihood ratio test was used to assess the independent
contribution of explanatory variables to the models. Statistical
significance was determined at the p#0.05 level, shown with 95%
confidence intervals (CI) throughout.
Ethics Approval
The study was approved by the Malawi National Health
Science Research and the Ethics Advisory Group of The
International Union Against Tuberculosis and Lung Disease,
Paris, France. The ethics committees waived the need for patient
consent because the study used routine programmatic data that
did not include any personal identifiers and were analysed
anonymously.
Results
Characteristics of re-treatment versus new cases
Between January 2006 and December 2008, 11,663 adult TB
cases were registered at MPC. Case registration data were
available for all TB patients. Of all TB registrations, 11,653
(99.9%) had smear microscopy: 3,094 (27%) had positive smear
results. A total of 1,384 (12%) were registered as ‘re-treatment
cases’. Compared to new TB cases, re-treatment cases were more
likely to be female (60% vs. 56%, p=0.04), older than 34 years
(55% vs. 45%, p,0.001), and less likely to have known HIV status
(58% vs. 63%, p,0.001) (Table 1). Among those with known
HIV status, re-treatment cases were more likely to be HIV-positive
(71% vs. 66%, p=0.006).
Characteristics of smear-negative ‘‘other’’ versus smear-
positive relapse, RAD and failure cases
Of 1,384 re-treatment cases, 898 (65%) were classified as smear-
negative ‘‘other’’; 406 (29%) as smear-positive relapse; 46 (4%) as
smear-positive RAD; and 34 (3%) as smear-positive failure.
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smear-negative ‘‘other’’ cases were older than 34 years and less
likely to have their HIV status ascertained. Among those with
known HIV status, ‘‘other’’ TB cases were more likely to be HIV-
positive (Table 2).
Treatment management
Of the 898 smear-negative ‘‘other’’ TB cases, 342 (38%)
received the category II re-treatment TB drug regimen while 462
(51%) were inappropriately managed on first-line treatment
regimen (2RHZE/4RH). Information on treatment regimen was
missing in 94 (10%) patients. A total of 348 (86%) relapse cases,
34(74%) RAD and 30 (88%) failure cases received the category II
regimens, indicating that significantly more smear-positive retreat-
ment cases received a category II regimen (p,0.001).
Treatment outcomes
Treatment outcomes were recorded for 663 (48%) of 1,384 re-
treatment cases. Of the 663, 585 (88%) had PTB and 78 (12%)
had EPTB. Treatment cards were missing for 721 (52%); these
patients were not included in further analysis. According to the
register, re-treatment patients with treatment cards were similar to
those without treatment cards in terms of age (p=0.194), sex
(p=0.557) TB classification (p=0.092) and place of TB treatment
(p=0.070). Of all outcomes, 66% were treatment success, 20%
loss to follow-up, 11% death, 2% transfer-out and 1% treatment
failure. Univariable analysis of re-treatment patients with treat-
ment cards showed that sex (p=0.003), treatment regimen
(p=0.033) and re-treatment category (p=0.050) were significantly
associated with treatment outcome; HIV status (p=0.683), age
(p=0.248) and year of registration (p=0.659) were not (Table 3).
Table 1. Distribution of patient characteristics by treatment
category (n=11,663 cases).
Characteristics New cases Re-treatment p-value
n% n %
Sex
Female 4,427 43% 556 40% 0.041
Male 5,852 57% 828 60%
Age
15–34 5,558 54% 620 45% ,0.001
$35 4,672 45% 764 55%
Unknown 49 1% 0 0%
HIV status
Positive 4,309 42% 575 41% ,0.001
Negative 2,182 21% 233 17%
Unknown 3,788 37% 576 42%
Smear status
¥
Positive 2,606 25% 486 35% ,0.001
Negative 7,671 75% 898 65%
Year of registration
2006 3,295 86% 531 14% ,0.001
2007 3,279 89% 426 11%
2008 3,705 90% 430 10%
¥2 cases had unknown smear status.
doi:10.1371/journal.pone.0028034.t001
Table 2. Distribution of patient characteristics by re-treatment category (n=1,384).
Characteristics Re-treatment P-value
¥
Total
Smear-positive
Relapse
Smear-positive
RAD
Smear-positive
Failure
Smear-negative
Other
Sex
Male 828 250 62% 35 76% 22 65% 521 58% 0.068
Female 556 156 38% 11 24% 12 35% 377 42%
Age
15–34 620 206 51% 33 71% 23 68% 358 40% 0.001
$35 764 200 49% 13 28% 11 32% 540 60%
HIV status
Positive 575 163 40% 21 46% 12 35% 379 42% 0.001
Negative 233 78 19% 16 35% 11 32% 128 14%
Unknown 576 165 41% 9 20% 11 32% 391 43%
Treatment regimen
First line: 2RHZE/4RH 500 28 7% 7 15% 3 9% 462 51% ,0.001
Re-treatment: 2SRHZE/1RHZE/RHE 754 348 86% 34 74% 30 88% 342 38%
Unknown 130 30 7% 5 11% 1 3% 94 10%
Year of registration
2006 528 145 36% 7 15% 11 32% 365 41% ,0.001
2007 426 139 34% 11 24% 16 47% 260 29%
2008 430 122 30% 28 61% 7 21% 273 30%
¥Chi-square test for the differences in the distribution of the categorical characteristic across patient re-treatment categories.
doi:10.1371/journal.pone.0028034.t002
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were more likely to have better treatment outcomes than males
(OR=1.68, 95% CI 1.20–2.37). Treatment success was also
significantly higher in smear-positive relapse patients than in the
smear-negative ‘‘other’’ (OR=1.58, 95% CI 1.09–2.28). There
was no significant difference in treatment success between smear-
positive RAD patients (57%, OR=0.76 CI 0.36–1.62) or smear-
positive failure (57%, OR=0.77 0.32–1.89) compared to smear-
negative ‘‘other’’. Multivariable analysis showed no significant
associated between treatment success and treatment regimen.
However, females had a higher probability of having good
treatment outcomes compared to males (OR=1.71, 95% CI
1.21–2.41). Treatment success rates remained higher among
smear-positive relapse compared with the smear-negative ‘‘other’’
(adjusted OR=1.63, 95% CI 1.09–2.45). Treatment success rates
were similar between the smear-negative ‘‘other’’ and smear-
positive RAD or smear-positive failure cases (smear-positive RAD
adjusted OR=0.86 95% CI 0.39–1.86; smear-positive failure
OR=0.85, 0.34–2.13). Re-treatment TB category did not modify
the association between treatment regimen and treatment
outcomes.
Discussion
This is the first study from a routine TB programme setting in
sub-Saharan Africa to explore characteristics and treatment
outcomes in previously-treated adult TB patients registered as
‘‘other’’. In this setting, 65% of the re-treatment cases were
classified as ‘‘other’’. Among ‘‘other’’, 75% had smear-negative
PTB, 75% were HIV-positive and most were men older than 34
years. The study also showed a high proportion of all TB cases had
smear microscopy results, indicating the TB programme per-
formed well. According to Malawi national TB guidelines, a re-
treatment regimen (2SRHZE/1RHZE/5RHE) should have been
used for all re-treatment cases. More than half of the patients
classified as ‘‘other’’ were inappropriately treated with the first-line
TB regimen (2RHZE/4RH). However, overall treatment success
rate was low among re-treatment TB patients receiving a category
II regimen, suggesting that this regimen may also not be the most
appropriate.
There are several possible explanations for the large number of
‘‘other’’ patients in this study. Many of these patients had smear-
negative TB and were HIV-positive, raising questions about
whether these were truly recurrent smear-negative PTB as a result
of re-infection or reactivation [8], or whether they had HIV-
related disease that was misdiagnosed as TB [9][10]. It is also
possible that these patients had other pulmonary or cardiac disease
that was misdiagnosed as TB [11]. Similar misdiagnosis might
have also occurred among EPTB cases because of their atypical
presentations. A previous study conducted in Malawi found that
16% of patients with an EPTB diagnoses did not have TB [12].
Adoption of new accurate diagnostic tools such as GeneXpert
MTB/RIF might help to reduce misdiagnosis in this group of
patients. We also noted uncertainty among some TB clinical
officers in other TB clinics as to how the ‘‘other’’ category should
be defined. Interestingly, WHO TB treatment guidelines considers
the ‘‘other’’ category as a variable group: ‘‘other’’ describes
patients who returned with smear-negative PTB or EPTB,
previously treated but with unknown outcome, or unknown
whether they were ever treated or not [13]. With such a sizeable
and heterogeneous group of ‘‘other’’ cases, more effort is needed to
classify these cases into clear, exhaustive, mutually-exclusive
categories. It may be worthwhile creating additional disease
categories from the ‘‘other’’ group such as ‘‘presumed re-treatment
TB’’ for patients with unknown previous treatment status; ‘‘smear-
negative re-treatment TB’’ for patients who return with smear-
negative PTB or EPTB; and ‘‘other re-treatment’’ for previously-
treated patients with unknown outcomes. Overall, better diagnos-
tic algorithms, improved access to mycobacterial culture facilities
or rapid and accurate TB diagnostic tests are needed to reduce
misdiagnosis and poor management.
Similar to other studies [14,15], we also observed low treatment
success rate among re-treatment cases. The most important reasons
for low treatment success rates were loss to follow-up (20%) and
death (11%). The highproportion of patients lost to follow-upmight
indicate a need for closer follow-up of this group during TB
treatment as loss to follow up may include hidden deaths. Also,
despite the overall low treatment outcome rates, the treatment
success rate for smear-positive relapse was significantly higher than
the treatment success rate in ‘‘other’’ TB patients after adjusting for
sex and age. There are various possible explanations. Relapse
patients have microbiologically-proven TB in contrast to ‘‘other’’
cases, which, as discussed above, may be a hybrid of true TB, HIV-
related disease and other pulmonary or cardiac disease. Given high
HIV infection rates in ‘‘other’’ cases and the inclusion of conditions
that may not respond to TB treatment, only a moderate proportion
Table 3. Distribution of patient characteristics by treatment
outcomes among re-treatment TB patients with treatment
cards (n=663).
Characteristics Treatment Outcome P-value
¥
n Successful
Not
successful
Total 663 435 228
Sex
Male 402 246 57% 156 68% 0.003
Female 261 189 43% 72 32%
Age
15–34 285 180 41% 105 46% 0.248
$35 378 255 59% 123 54%
HIV status
Positive 309 204 47% 105 46% 0.683
Negative 146 99 23% 47 21%
Unknown 208 132 30% 76 33%
Re-treatment category
Smear-positive Relapse 204 149 34% 55 24% 0.050
Smear-positive RAD 30 17 4% 13 6%
Smear-positive Failure 21 12 2% 9 4%
Smear-negative ‘‘other’’
(EPTB, PTB)
407 257 59% 150 66%
Treatment regimen
First line: 2RHZE/4RH 214 144 67% 70 33% ,0.033
Re-treatment: 2SRHZE/
1RHZE/RHE
411 274 67% 137 33%
Unknown 37 17 46% 20 54%
Year of registration
2006 181 118 65% 63 35% 0.659
2007 189 120 63% 69 37%
2008 292 197 67% 95 33%
¥Chi-square test,
doi:10.1371/journal.pone.0028034.t003
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management). This is consistent with the 63% TB treatment
success rate in the ‘‘other’’ group, and the inappropriate use of first-
line TB regimen would not have adversely affected clinical
outcomes in such patients. It is also likely that many HIV-infected
smear-negative ‘‘other’’ TB category patients were more immune-
compromised than relapse smear-positive PTB patients, resulting in
poorer outcomes [16]. As this study was retrospective, we have no
means of further investigating these issues. Generally, the re-
treatment group had low re-treatment failure rates which may
indicate a low prevalence of MDR-TB, although this does require
more in depth study. Our results also showed that males had lower
treatment success rates and were more likely to default or die while
on TB treatment, and this may reflect low compliance with TB
treatment therapy [17,18].
Although neither the WHO nor The International Union
Against Tuberculosis and Lung Disease TB treatment guidelines
provide clear guidance on what regimen should be given to
patients classified as ‘‘other’’, the current Malawi National TB
treatment guidelines recommend re-treatment drug regimens for
all ‘‘other’’ TB patients. However, less than half of ‘‘other’’ TB
patients in our study were treated with a category II regimen,
suggesting clinician’s uncertainty about this category of TB
patients, rather than a general failure to follow guidelines. Other
countries treat ‘‘other’’ TB patients with a first-line regimen if their
smear is negative because they are considered to be at lower risk of
failure and developing resistance. However, some previous studies
observed generally low treatment success rates among smear
positive re-treatment TB patients treated with the category II
regimen [15,19]. Given the poor treatment outcomes also
observed in these ‘‘other’’ re-treatment groups, it is certainly
worthwhile and important to review the current category II
regimen for re-treatment TB patients. These patients may be at
high risk of drug resistance and of developing MDR, as was seen in
South Africa [20].
Our findings should be viewed with the following limitations.
First, 52% of treatment cards for re-treatment patients were
missing although all treatment cards should have been returned to
the MPC TB registration centre at the time of this study. Some
cards might have been lost at the peripheral sites or within the TB
registry, introducing bias if patients without treatment cards had
different outcomes than those with treatment cards. However, we
observed no differences in terms of demographics, TB classifica-
tion and place of treatment between patients with and without
treatment cards. Second, although TB outcome data were
supposed to be recorded on treatment cards and in the TB
register, a considerable proportion of adverse outcomes were not
recorded in the TB registers. As treatment cards are the primary
source of outcome information, we based the analysis on outcomes
documented on the cards and not the register. Exclusion of
patients with missing cards may have resulted in a biased selection
of patients with better treatment outcomes, assuming that cards of
defaulters were more likely to be lost. Despite these limitations, the
study findings are useful to inform policy and programs in Malawi
and other comparable settings to improve care for TB patients.
In conclusion, our study shows that the ‘‘other’’ TB category
constitutes a sizeable population of re-treatment patients and is
poorly managed. Accurate definitions and categories from the
current ‘‘other’’ category should be created to avoid poor patient
management. The high proportion of missing treatment cards
suggests that less priority is given to these re-treatment patients.
Treatment success may be improved by adoption of more accurate
diagnostic tools such as Xpert MTB/RIF and more rigorous
training and regular supervision of TB staff. There is also a need to
reappraise the category II regimen as our results suggest that use of
this regimen is not associated with successful outcomes. Some of
these issues are currently under discussion within the Malawi NTP
with the aim of improving routine programme management.
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Table 4. Factors associated with binary treatment success rate among TB treatment classification (n=663).
Characteristics N Unadjusted Odds Ratio (95% CI) P-value* Adjusted
F - Odds Ratio (95% CI) P-value*
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Male 402 1.00 1.00
Age
15–34 285 0.82 (0.59–1.13) 0.229 0.79 (0.55–1.11) 0.170
$35 378 1.00 1.00
Re-treatment category
Smear-positive Relapse 204 1.58 (1.09–2.28) 0.047 1.63 (1.09–2.45) 0.065
Smear-positive RAD 30 0.76 (0.36–1.62) 0.86 (0.39–1.86)
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Treatment regimen
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